AbbVie vs Eli Lilly and at a glance
Both companies operate in the Health Care sector, so these figures are broadly like-for-like.
| Metric | ABBV | LLY |
|---|---|---|
| Market cap | $453.22B | $1.04T |
| Price | $255.48 | $1,174.61 |
| P/E ratio (TTM) | 95.29 | 46.69 |
| P/B ratio (MRQ) | 0 | 36.31 |
| P/S ratio (TTM) | 6.58 | 14.78 |
| Revenue growth (1Y) | 8.57% | 44.70% |
| Return on equity (TTM) | -129.24% | 77.78% |
| Return on invested capital (TTM) | 21.13% | 34.50% |
| Gross margin (TTM) | 73.70% | 84.01% |
| Net margin (TTM) | 5.79% | 33.53% |
| Dividend yield (TTM) | 2.71% | 0.59% |
How they differ
Eli Lilly and is the larger company at $1.04T versus $453.22B — about 2.3x the size.
On trailing earnings, Eli Lilly and is the cheaper of the two at 46.69 against 95.29 for AbbVie.
On sales, AbbVie is the cheaper of the two at 6.58 against 14.78 for Eli Lilly and.
Eli Lilly and leads on revenue growth over the past year, 44.70% against 8.57%.
Eli Lilly and leads on return on invested capital, 34.50% against 21.13%.
Eli Lilly and leads on gross margin, 84.01% against 73.70%.
AbbVie offers the higher yield at 2.71% against 0.59%.
Go deeper
Ratios describe the past. Whether either is worth owning depends on what you pay today.
Related comparisons
Other matchups involving AbbVie or Eli Lilly and.